Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2024 RESULTS SANTA MONICA, Calif. -- (May 9, 2024) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights Exhibit 99.1 Revenue and Adjusted Revenue increased 8% to $197.9 million compared to $184.0 million. Prescription transactions revenue increased 8% to $145.4 million compar ...

GoodRx Holdings Inc (NASDAQ:GDRX) stock is up 1.9% to trade at $6.87 this morning, after Keybanc upgraded the digital healthcare service to "overweight" from "sector weight," while setting a price target of $9. The analyst in coverage cited the potential for strong subscriber growth, as well as a positive shift in the company's monthly active users (MAUs). GoodRx  jumped nearly 4% premarket, but broad market headwinds are capping gains. The stock has support at its 80-day moving average, which has propped u ...

GoodRx Holdings, Inc. (GDRX) closed the last trading session at $6.77, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.74 indicates a 29.1% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $2.19. While the lowest estimate of $5 indicates a 26.1% decline from the current price level, the most optimistic analyst exp ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced Interim CEO Scott Wagner has extended his commitment to the Company. In addition, Stephen LeSieur and Adam Karol have notified GoodRx of their decision to resign from the Company’s Board of Directors, effective March 14, 2024 and March 22, 2024, respectively. “I’m encouraged by the progress the team is making and happy to see the hard work start showin ...

GoodRx Holdings, Inc. (GDRX) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate re ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

GoodRx Holdings, Inc. (GDRX) reported $196.64 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 6.8%. EPS of $0.08 for the same period compares to $0.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $195.59 million, representing a surprise of +0.54%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.08.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...

Shares of GoodRx Holdings (GDRX 20.40%) rallied by 20.4% on Thursday after the company announced stronger-than-expected quarterly results and a new stock buyback program.A solid quarterIn the fourth quarter, GoodRx's revenue grew 7% year over year to $196.6 million, translating to adjusted (non-GAAP) net income of $31.1 million, or $0.08 per share, up from $0.07 per share in the prior-year period. Analysts, on average, were only modeling for earnings of $0.07 per share on slightly lower revenue. GoodRx ende ...

Financial Data and Key Metrics Changes - In Q4 2023, adjusted revenue increased by 7% year-over-year to $196.6 million, primarily driven by organic growth in prescription transactions revenue [34][67] - Adjusted EBITDA margin improved by 220 basis points year-over-year to approximately 29.1%, with adjusted EBITDA growing 15% year-over-year to $57.3 million [34][23] - Net loss for Q4 2023 was $25.9 million, compared to a net loss of $2.0 million in Q4 2022 [23] Business Line Data and Key Metrics Changes - Subscription revenue declined by 6% to $23.1 million due to the wind down of Kroger Savings Club, with Gold subscription count increasing both quarter-over-quarter and year-over-year [22] - Prescription transactions revenue grew by 11% year-over-year to $143.9 million, an acceleration from Q3 growth [45] - Pharma Manufacturer Solutions revenue declined by 2% year-over-year to $24.4 million, impacted by the restructuring and shutdown of vitaCare [46] Market Data and Key Metrics Changes - Over 25 million consumers used GoodRx in 2023, achieving approximately $15 billion in prescription savings [9] - The company estimates that over 75% of GoodRx users have some form of insurance coverage, indicating a significant market for price comparison against co-pays [15] Company Strategy and Development Direction - The company is focused on strengthening retail pharmacy relationships and enhancing its hybrid model, which includes both direct contracting and PBM partnerships [36] - GoodRx plans to continue investing in advertising and promotion, with over $200 million spent in 2023 to increase user numbers and drive prescription volume [14] - The company anticipates adjusted revenue of about $800 million for 2024, representing a growth rate of approximately 5% [71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing increasing patient out-of-pocket costs and the essential role of GoodRx in the healthcare system [32][33] - The company expects continued revenue growth in Q1 2024, with adjusted revenue guidance of $195 million to $198 million [48] - Management acknowledged the impact of recent outages disclosed by UnitedHealth Group but indicated that the effect on financials was likely minimal [48][94] Other Important Information - The company ended Q4 2023 with $672.3 million in cash and cash equivalents and $661.8 million of outstanding debt [47] - A new stock repurchase program was approved to repurchase up to $450 million worth of Class A common stock [70] Q&A Session All Questions and Answers Question: What does GoodRx look like in 5-10 years? - Management indicated that the future model will likely remain a combination of PBM network relationships and direct retail partnerships, evolving but not drastically changing [76] Question: Can you elaborate on the ISP opportunity? - Management noted that while there is a significant opportunity with PBM partners, the rollout is still in early stages, and they are focused on expanding lives covered [56][80] Question: How does the ISP margin compare to traditional business? - Management stated that over time, ISP margins are expected to be similar to the rest of the business, with demand captured differently [59] Question: What is the impact of recent system outages? - Management explained that their tech teams effectively created alternatives to minimize the impact of outages, which were brief and did not significantly affect financials [94][116] Question: Are any direct contracting agreements exclusive? - Management clarified that direct contracting agreements are not exclusive, and GoodRx remains the leading company in the cash discount card space [132]

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.06, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates two times.GoodRx Holdings, Inc., which belon ...